The specialist healthcare investment firm LSP (Life Sciences Partners) and Bristol-Myers Squibb entered a strategic collaboration to identify European breakthrough technologies and products in immuno-oncology and other areas of unmet medical need. The operation represents the first investment made by Bristol-Myers Squibb in a European healthcare fund. A representative of Bristol-Myers Squibb will be joining the LSP 5 Advisory Board.

LSP (Life Sciences Partners) is an independent European investment firm, providing financing for private and public life-science companies. Since the late 1980s, LSP’s management has invested in a large number of highly innovative enterprises.